Travere Therapeutics (TVTX) News Today $16.60 -0.96 (-5.47%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$16.40 -0.20 (-1.20%) As of 05/21/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory reviewMay 21 at 11:56 PM | investing.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Rafferty Asset Management LLCRafferty Asset Management LLC boosted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 92.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 176,425 shares of the companMay 21 at 5:41 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXMay 20 at 6:06 PM | prnewswire.comTravere Therapeutics: Establishing A Position After Last Week's SelloffMay 20 at 4:16 PM | seekingalpha.comDeutsche Bank AG Lowers Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Deutsche Bank AG lessened its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 24.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 532,031 shares of the company's stock after sellingMay 19 at 4:12 AM | marketbeat.comThe Manufacturers Life Insurance Company Reduces Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)The Manufacturers Life Insurance Company decreased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 41.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,338 shares of the companMay 19 at 3:17 AM | marketbeat.comSphera Funds Management LTD. Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Sphera Funds Management LTD. boosted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 29.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 220,700 shares of the companMay 18, 2025 | marketbeat.comNorthern Trust Corp Has $13.14 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Northern Trust Corp grew its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 754,395 shares of the company's stock afMay 18, 2025 | marketbeat.comTravere Therapeutics stock falls on FDA review setbackMay 16, 2025 | in.investing.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC raised its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,117,792 shares of the company's stock after buying an additioMay 16, 2025 | marketbeat.comTravere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGSMay 15, 2025 | businesswire.comAlgert Global LLC Invests $282,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX)Algert Global LLC purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 16,167 shares of the company's stock, valued at approximately $2May 15, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Reduced by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lessened its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 85.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 39,604 shares of the comMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Integral Health Asset Management LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 100,000 shares oMay 14, 2025 | marketbeat.comJ. Goldman & Co LP Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)J. Goldman & Co LP purchased a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 181,174 shares of the company's stock, valued at approxiMay 14, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $37.88 Million Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Jacobs Levy Equity Management Inc. grew its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 36.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,174,213 shares of the company's stock afMay 14, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 152,820 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Schonfeld Strategic Advisors LLC cut its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 86.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,000 shares of the company's stock after selling 152,May 13, 2025 | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | businesswire.comBrevan Howard Capital Management LP Sells 30,742 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Brevan Howard Capital Management LP decreased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 49.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,953 shares of the compMay 12, 2025 | marketbeat.com1,209,810 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets bought a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 1,209,810 shares of the company's stock, valued at approximately $21,075,000. BNP Paribas Financial MaMay 12, 2025 | marketbeat.comDriehaus Capital Management LLC Has $38.64 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Driehaus Capital Management LLC increased its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 608.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,217,975May 11, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Crestline Management LPCrestline Management LP increased its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 53.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,840 shares of the company's stock after acquMay 10, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stake Boosted by AQR Capital Management LLCAQR Capital Management LLC boosted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 117.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 424,024 shares of the company's stock after purchasMay 10, 2025 | marketbeat.comHsbc Holdings PLC Has $487,000 Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Hsbc Holdings PLC reduced its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 33.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 27,835 shares of the company's stock after selling 13,981 shares during the period. Hsbc Holdings PLC's holdMay 9, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $37,279.55 in StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 1,771 shares of Travere Therapeutics stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,279.55. Following the completion of the transaction, the insider now owns 128,215 shares of the company's stock, valued at approximately $2,698,925.75. The trade was a 1.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.May 8, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CFO Sells $37,553.20 in StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher R. Cline sold 1,784 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,553.20. Following the transaction, the chief financial officer now directly owns 93,126 shares of the company's stock, valued at approximately $1,960,302.30. The trade was a 1.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.May 8, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CEO Sells $398,350.20 in StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric M. Dube sold 18,924 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $398,350.20. Following the sale, the chief executive officer now owns 419,173 shares in the company, valued at approximately $8,823,591.65. The trade was a 4.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 8, 2025 | marketbeat.comTravere Therapeutics to Participate at Upcoming Investor ConferencesMay 7, 2025 | businesswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 1,771 SharesMay 7, 2025 | insidertrades.comFreestone Grove Partners LP Takes Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Freestone Grove Partners LP bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 25,521 shares of the company's stock, valued at approximately $445,000May 6, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of "Moderate Buy" from AnalystsTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fifteen research firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have gMay 6, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Posts Earnings Results, Beats Expectations By $0.08 EPSTravere Therapeutics (NASDAQ:TVTX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The firm had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. During the same period in the prior year, the company posted ($1.76) EPS. The company's revenue was up 83.3% on a year-over-year basis.May 5, 2025 | marketbeat.comAnalysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter ReportMay 4, 2025 | finance.yahoo.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $23.00 at Stifel NicolausStifel Nicolaus raised their price objective on shares of Travere Therapeutics from $22.00 to $23.00 and gave the company a "hold" rating in a research report on Friday.May 4, 2025 | marketbeat.comAquatic Capital Management LLC Invests $557,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX)Aquatic Capital Management LLC acquired a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 31,967 shares of the company's stock, valued at approximately $557May 4, 2025 | marketbeat.comRA Capital Management L.P. Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)RA Capital Management L.P. acquired a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,150,000 shares of the company's sMay 3, 2025 | marketbeat.comTower Research Capital LLC TRC Grows Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Tower Research Capital LLC TRC grew its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 211.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,367 shares of the company'sMay 3, 2025 | marketbeat.comCANADA LIFE ASSURANCE Co Acquires 16,416 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)CANADA LIFE ASSURANCE Co raised its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 237.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,318 shares of the company'sMay 3, 2025 | marketbeat.comTravere Therapeutics’ Earnings Call: Growth Amid ChallengesMay 2, 2025 | tipranks.comTravere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comTravere Therapeutics, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 1, 2025 | seekingalpha.comTravere Therapeutics Reports First Quarter 2025 Financial ResultsMay 1, 2025 | businesswire.comPDT Partners LLC Cuts Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)PDT Partners LLC cut its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 6.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 247,109 shares of the company's stock after selling 17,164 shares during the period. PDT Partners LLC owned apMay 1, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Sells 83,935 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Emerald Mutual Fund Advisers Trust lowered its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,101,774 shares of the company's stock after selling 83,935 shareMay 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $6.56 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Adage Capital Partners GP L.L.C. trimmed its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 376,800 shares of the cMay 1, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Up 6% - What's Next?Travere Therapeutics (NASDAQ:TVTX) Shares Up 6% - Still a Buy?April 30, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Virtus ETF Advisers LLCVirtus ETF Advisers LLC reduced its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 57.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,523 shares of the company's stock after selling 25,967 shares during the quarter. Virtus ETF AdApril 30, 2025 | marketbeat.comTravere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA NephropathyApril 29, 2025 | finance.yahoo.comCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA NephropathyApril 29, 2025 | prnewswire.comTravere Therapeutics (TVTX) to Release Quarterly Earnings on ThursdayTravere Therapeutics (NASDAQ:TVTX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-travere-therapeutics-inc-stock/)April 28, 2025 | marketbeat.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼1.040.65▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼137▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Verona Pharma News Today Telix Pharmaceuticals Limited American Depositary Shares News Today TG Therapeutics News Today Grifols News Today Lantheus News Today Legend Biotech News Today Axsome Therapeutics News Today Nuvalent News Today ADMA Biologics News Today Vaxcyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVTX Stock Free TVTX Stock Alerts